Lasa Supergenerics Reports Significant Decline in Financial Performance for Q1 2024

Lasa Supergenerics, a microcap pharmaceutical company, recently announced its financial results for the quarter ending March 2024. The company has seen a significant decline in its financial performance, with a score of -20 compared to -6 in the previous quarter.

One of the major factors contributing to this decline is the decrease in net sales, which have fallen by -35.39% year on year. This trend is expected to continue in the near term, indicating a negative sales outlook for the company.

The company's profit before tax (PBT) less other income has also seen a sharp decline of -2904.17% year on year. This is reflected in the negative PBT trend in the near term. Similarly, the profit after tax (PAT) has also fallen by -233.3% year on year, indicating a negative trend in the near term.

In addition, Lasa Supergenerics has recorded its lowest net sales and operating profit (PBDIT) in the last five quarters. The operating profit margin has also decreased to -17.44%, indicating a decline in the company's efficiency.

The PBT less other income has also reached its lowest point in the last five quarters, further highlighting the negative trend in the company's financial performance. The earnings per share (EPS) have also decreased to Rs -3.05, indicating a decline in profitability and lower earnings for shareholders.

Based on these financial results, MarketsMOJO has given a 'Strong Sell' call for Lasa Supergenerics' stock. Investors should carefully consider these factors before making any investment decisions.